Abstract

Allergen-specific immunotherapy is considered an effective therapy for the management of canine atopic dermatitis when relevant allergens have been identified through either intradermal or serological testing. It is an extremely safe form of treatment and serious adverse effects are uncommon. Additional anti-inflammatory or symptomatic therapy during the induction phase of immunotherapy is often needed, depending on the severity of clinical signs in the individual. The long-term success of immunotherapy can be measured by the ability to taper or even withdraw these supportive therapies.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.